What is Synapticure?
Synapticure is a specialized healthcare technology company dedicated to revolutionizing the standard of care for people living with Amyotrophic Lateral Sclerosis (ALS). Headquartered in Chicago, the company operates at the intersection of clinical excellence and digital innovation. By building a platform designed by and for the ALS community, in collaboration with leading clinicians, Synapticure provides a comprehensive, personalized care experience that extends directly into the patient's home. The company's market position is defined by its commitment to evidence-based, patient-centric care, aiming to dismantle the traditional barriers that often hinder effective treatment and support for those navigating neurodegenerative conditions.
How much funding has Synapticure raised?
Synapticure has raised a total of $31M across 2 funding rounds:
Angel/Seed
$6M
Series A
$25M
Angel/Seed (2022): $6M with participation from David Hodgson, Gerald E. Bisbee, Jeff Huber, Adam Koppel, Rohan Seth, Ben and Divya Silbermann, Martin Ventures, Ron Conway, Lifeforce Capital Gp I, Joe Kraus, Byers Capital, Y Combinator, and GV
Series A (2024): $25M led by GV, CVS Health, B Capital Group, and RA Capital Management
Key Investors in Synapticure
GV
GV is a venture capital firm that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
CVS Health
CVS Health is a diversified healthcare company providing pharmacy care, health benefits, and consumer health solutions with a focus on improving access and affordability.
B Capital Group
B Capital is a global venture capital firm that empowers entrepreneurs by investing in early and late-stage companies within the technology and healthcare sectors.
What's next for Synapticure?
With the successful closure of its latest financing round, Synapticure is poised to enter a new phase of operational scaling and service enhancement. The strategic capital will likely be deployed to broaden the company's clinical network, refine its digital care delivery platform, and invest in research-backed initiatives that improve patient outcomes. As the firm transitions from its initial growth phase into a more mature enterprise, the focus will remain on maintaining the high standard of personalized care that has become its hallmark. By leveraging its strong investor base and deep clinical partnerships, Synapticure is set to influence the future of neurodegenerative disease management, potentially setting a new benchmark for how specialized, home-based care is delivered at scale.
See full Synapticure company page
